261 related articles for article (PubMed ID: 28398413)
1. Imatinib mesylate-induced lichenoid drug eruption.
Penn EH; Chung HJ; Keller M
Cutis; 2017 Mar; 99(3):189-192. PubMed ID: 28398413
[TBL] [Abstract][Full Text] [Related]
2. Lichenoid drug eruption associated with imatinib mesylate therapy.
Alexandris D; Alevizopoulos N; Marinos L; Kanellis G; Gakiopoulou C
J Oncol Pharm Pract; 2023 Jan; 29(1):252-257. PubMed ID: 35473395
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate-induced severe lichenoid rash.
; De D; Malhotra P; Saikia UN
Indian J Dermatol Venereol Leprol; 2014; 80(1):93-5. PubMed ID: 24448145
[No Abstract] [Full Text] [Related]
4. Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature.
Kuraishi N; Nagai Y; Hasegawa M; Ishikawa O
Acta Derm Venereol; 2010; 90(1):73-6. PubMed ID: 20107730
[TBL] [Abstract][Full Text] [Related]
5. Adverse skin effects of imatinib, a tyrosine kinase inhibitor.
Pretel-Irazabal M; Tuneu-Valls A; Ormaechea-Pérez N
Actas Dermosifiliogr; 2014 Sep; 105(7):655-62. PubMed ID: 23642471
[TBL] [Abstract][Full Text] [Related]
6. Oral lichenoid reaction to imatinib (STI 571, Gleevec).
Lim DS; Muir J
Dermatology; 2002; 205(2):169-71. PubMed ID: 12218235
[TBL] [Abstract][Full Text] [Related]
7. Oral and cutaneous lichenoid reaction with nail changes secondary to imatinib: report of a case and literature review.
Wahiduzzaman M; Pubalan M
Dermatol Online J; 2008 Dec; 14(12):14. PubMed ID: 19265627
[TBL] [Abstract][Full Text] [Related]
8. Clinical and histopathologic analysis of 46 cases of cutaneous adverse reactions to imatinib.
Lee WJ; Lee JH; Won CH; Chang SE; Choi JH; Moon KC; Kang YK; Lee MW
Int J Dermatol; 2016 May; 55(5):e268-74. PubMed ID: 26680344
[TBL] [Abstract][Full Text] [Related]
9. Imatinib-induced lichen planus and lichenoid drug eruption: A report of three cases.
Almheirat Y; Bouabdalla S; Daflaoui H; Zizi N; Dikhaye S
J Cutan Pathol; 2023 May; 50(5):415-419. PubMed ID: 36789996
[TBL] [Abstract][Full Text] [Related]
10. Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients.
Vinay K; Yanamandra U; Dogra S; Handa S; Suri V; Kumari S; Khadwal A; Prakash G; Lad D; Varma S; Malhotra P
Int J Dermatol; 2018 Mar; 57(3):332-338. PubMed ID: 29266186
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A six-year follow up.
Dervis E; Ayer M; Akin Belli A; Barut SG
Eur J Dermatol; 2016 Apr; 26(2):133-7. PubMed ID: 26679005
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate.
Scheinfeld N
J Drugs Dermatol; 2006 Mar; 5(3):228-31. PubMed ID: 16573254
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous manifestations in chronic myeloid leukemia in chronic phase treated with imatinib.
Khokar A; Malik U; Butt G; Naumeri F
Int J Dermatol; 2019 Sep; 58(9):1098-1101. PubMed ID: 31241173
[TBL] [Abstract][Full Text] [Related]
14. Lichenoid drug eruption caused by imatinib mesylate in a Chinese patient with gastrointestinal stromal tumor.
Luo JR; Xiang XJ; Xiong JP
Int J Clin Pharmacol Ther; 2016 Sep; 54(9):719-22. PubMed ID: 27345285
[TBL] [Abstract][Full Text] [Related]
15. [Lichenoid cutaneous reaction to imatinib].
Roux C; Boisseau-Garsaud AM; Saint-Cyr I; Hélénon R; Quist D; Delaunay C
Ann Dermatol Venereol; 2004; 131(6-7 Pt 1):571-3. PubMed ID: 15318140
[TBL] [Abstract][Full Text] [Related]
16. Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity.
Musolino C; Allegra A; Mannucci C; Russo S; Alonci A; Maisano V; Calapai G; Gangemi S
Turk J Haematol; 2015 Jun; 32(2):168-71. PubMed ID: 26316486
[TBL] [Abstract][Full Text] [Related]
17. Oral lichenoid eruption associated with imatinib treatment.
Gómez Fernández C; Sendagorta Cudós E; Casado Verrier B; Feito Rodríguez M; Suárez Aguado J; Vidaurrázaga Díaz de Arcaya C
Eur J Dermatol; 2010; 20(1):127-8. PubMed ID: 19825526
[No Abstract] [Full Text] [Related]
18. Terbinafine-induced lichenoid drug eruption.
Zheng Y; Zhang J; Chen H; Lai W; Maibach HI
Cutan Ocul Toxicol; 2017 Mar; 36(1):101-103. PubMed ID: 26938740
[TBL] [Abstract][Full Text] [Related]
19. Lichen planopilaris-like eruption during treatment with tyrosine kinase inhibitor nilotinib.
Leitão JR; Valente NY; Kakizaki P; Veronez IS; Pires MC
An Bras Dermatol; 2016; 91(5 suppl 1):45-47. PubMed ID: 28300891
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
